Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer.

Abstract

The purpose of this study was to assess the toxicoses and antitumor activity of metronomic chlorambucil at a dosage of 4 mg m(-2) daily in dogs with naturally occurring cancer. Thirty-six dogs were enrolled in the study. The protocol was well tolerated with no grade 3 or 4 toxicoses noted. Complete remission was achieved, and lasted over 35 weeks in three dogs (mast cell tumour, soft tissue sarcoma and thyroid carcinoma). Partial remission was noted in 1 dog with histiocytic sarcoma (39 weeks duration) for an overall remission rate of 11% (4 of 36). Stable disease was noted in 17 dogs (47%) with various other cancers. The median progression-free interval was 61 days, and the median survival time was 153 days. Chlorambucil given in a metronomic protocol showed antitumor activity in dogs with a variety of naturally occurring cancers.

• Authors: T N Leach, M O Childress, S N Greene, A S Mohamed, G E Moore, D R Schrempp, S R Lahrman, D W Knapp
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 10 Issue 2 Pg. 102-12 (Jun 2012) ISSN: 1476-5829 [Electronic] England
• PMID: 22236329 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2011 Blackwell Publishing Ltd.

Chemical References

• Antineoplastic Agents, Alkylating
• Chlorambucil

Topics

• Administration, Metronomic
• Animals
• Antineoplastic Agents, Alkylating (administration & dosage, therapeutic use)
• Chlorambucil (administration & dosage, therapeutic use)
• Dog Diseases (drug therapy)
• Dogs
• Female
• Male
• Neoplasms (drug therapy, veterinary)
• Prospective Studies